Table 2.
The pooled ORs and 95%CIs for the association between TNF polymorphisms and prostate cancer susceptibility in total and stratified analysis
| Variables | N | Case/Control | M-allele vs. W-allele OR(95%CI) PhP |
MW vs. WW OR(95%CI) PhP |
MM + MW vs. WW OR(95%CI) PhP |
|---|---|---|---|---|---|
| rs1800629 | |||||
| Total | 22 | 6936/7619 | 1.03 (0.92–1.16)0.001 0.580 | 1.04 (0.93–1.17)0.040 0.486 | 1.06 (0.94–1.18)0.013 0.353 |
| HWE | 18 | 7485/6792 | 1.03 (0,92–1.16)0.006 0.584 | 1.04 (0,93–1.16)0.091 0.509 | 1.05 (0,94–1.17)0.051 0.429 |
| Ethnicity | |||||
| Asian | 8 | 964/1137 | 1.03 (0.68–1.56)0.000 0.881 | 1.04 (0.70–1.56)0.038 0.845 | 1.09 (0.70–1.71)0.006 0.698 |
| Caucasian | 12 | 5626/5817 | 1.01 (0.94–1.08)0.223 0.838 | 1.02 (0.94–1.11)0.525 0.672 | 1.02 (0.94–1.11)0.433 0.625 |
| African-American | 2 | 346/665 | 0.93 (0.47–1.86)0.049 0.843 | 0.87 (0.28–2.67)0.009 0.804 | 0.90 (0.34–2.37)0.016 0.829 |
| SOC | |||||
| HB | 14 | 2579/2973 | 1.02 (0.86–1.22)0.012 0.787 | 1.00 (0.81–1.22)0.023 0.972 | 1.01 (0.82–1.24)0.012 0.787 |
| PB | 8 | 4357/4646 | 1.04 (0.89–1.22)0.009 0.600 | 1.04 (0.94–1.14)0.298 0.483 | 1.04 (0.95–1.14)0.199 0.425 |
| Genotyping | |||||
| Others | 5 | 977/1309 | 1.07 (0.91–1.26)0.420 0.420 | 0.97 (0.62–1.53)0.021 0.900 | 1.07 (0.79–1.45)0.079 0.668 |
| Sequencing | 2 | 546/530 | 0.94 (0.75–1.19)0.166 0.608 | 0.76 (0.34–1.70)0.055 0.505 | 0.80 (0.41–1.55)0.086 0.506 |
| TaqMan | 7 | 4456/4733 | 1.04 (0.92–1.17)0.081 0.520 | 1.02 (0.93–1.12)0.278 0.638 | 1.02 (0.93–1.12)0.152 0.672 |
| PCR-RFLP | 5 | 463/562 | 0.74 (0.43–1.28)0.030 0.280 | 0.90 (0.63–1.29)0.263 0.565 | 0.89 (0.63–1.26)0.186 0.520 |
| ARMS-PCR | 3 | 494/485 | 1.56 (0.74–3.29)0.001 0.239 | 1.28 (0.93–1.78)0.163 0.135 | 1.54 (0.80–2.97)0.024 0.192 |
| rs361525 | |||||
| Total | 8 | 2212/2222 | 0.93 (0.66–1.32)0.007 0.684 | 0.86 (0.52–1.41)0.000 0.542 | 0.85 (0.52–1.39)0.000 0.525 |
| HWE | 6 | 2043/1979 | 1.11 (0,91–1.35)0.111 0.321 | 1.02 (0,69–1.52)0.055 0.905 | 1.05 (0,73–1.52)0.803 0.794 |
| Ethnicity | |||||
| Asian | 3 | 450/470 | 0.72 (0.34–1.50)0.039 0.380 | 0.55 (0.15–1.99)0.002 0.360 | 0.54 (0.15–2.00)0.001 0.357 |
| Caucasian | 4 | 1698/1624 | 1.16 (0.94–1.44)0.673 0.164 | 1.16 (0.94–1.44)0.673 0.164 | 1.16 (0.94–1.44)0.673 0.164 |
| African-American | 1 | 64/126 | – | – | – |
| Genotyping | |||||
| Others | 2 | 178/188 | 0.65 (0.47–0.89)0.111 0.008 | 0.44 (0.09–2.25)0.002 0.326 | 0.44 (0.08–2.28)0.002 0.325 |
| Sequencing | 2 | 535/511 | 1.07 (0.72–1.57)0.595 0.746 | 0.90 (0.59–1.38)0.590 0.633 | 0.98 (0.65–1.48)0.999 0.936 |
| PCR-RFLP | 2 | 140/150 | 2.59 (0.98–6.85)0.628 0.055 | 2.68 (1.00–7.20)0.626 0.050 | 2.68 (1.00–7.20)0.626 0.050 |
| TaqMan | 2 | 1359/1371 | 0.77 (0.30–2.01)0.017 0.599 | 0.78 (0.28–2.20)0.011 0.640 | 0.77 (0.28–2.13)0.013 0.620 |
| rs1799724 | |||||
| Total | 5 | 2914/3121 | 0.95 (0.84–1.07)0.169 0.381 | 1.01 (0.80–1.27)0.054 0.951 | 0.95 (0.83–1.07)0.120 0.390 |
| HWE | 3 | 2444/2735 | 0.99 (0,78–1.26)0.042 0.930 | 0.98 (0,74–1.30)0.037 0.896 | 0.99 (0,75–1.30)0.032 0.931 |
| Caucasian | 3 | 2253/2493 | 0.90 (0.79–1.03)0.403 0.115 | 0.88 (0.76–1.02)0.196 0.082 | 0.88 (0.76–1.02)0.400 0.089 |
Ph: value of Q-test for heterogeneity test; P: Z-test for the statistical significance of the OR; HB hospital-based, PB population-based, SOC source of control, PCR-FLIP polymerase chain reaction and restrictive fragment length polymorphism, ARMS amplification refractory mutation system HWE, Hardy–Weinberg equilibrium of control group, W wild type-allele, M mutant-allele